(Q40845274)

24 September 2017

1 reference

title

New drugs in the treatment of colorectal carcinoma (English)

1 reference

24 September 2017

C J Punt

1

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 August 1998

1 reference

24 September 2017

1 reference

24 September 2017

volume

83

1 reference

24 September 2017

issue

4

1 reference

24 September 2017

page(s)

679-689

1 reference

The chemotherapy of colon cancer can no longer be ignored

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Topoisomerase I inhibitors: topotecan and irenotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Clinical, pharmacokinetic and biological studies of topotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Patients treated with a monoclonal antibody (ab1) to the colorectal carcinoma antigen 17-1A develop a cellular response (DTH) to the "internal image of the antigen" (ab2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Tallimustine in advanced previously untreated colorectal cancer, a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

'Tomudex' (ZD1694): A novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

A pilot study of combination therapy with interferon-alpha-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase I-II studies of oral tegafur (ftorafur)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

A phase II study of trimetrexate therapy for metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase I Trial of Multiple Large Doses of Murine Monoclonal Antibody CO17-1A. II. Pharmacokinetics and Immune Response1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase II trial of edatrexate in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

Phase II study of gemcitabine in advanced colorectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980815%2983%3A4%3C679%3A%3AAID-CNCR8%3E3.0.CO%3B2-F

10.1002/(SICI)1097-0142(19980815)83:4<679::AID-CNCR8>3.0.CO;2-F

21 January 2018

Identifiers

DOI

1 reference

24 September 2017

1 reference